NCODA Logo

NEWS

Advancements in Patient-Centered Care

Stay up to date with the latest advancements in oral oncolytics, medically-integrated oncology, and cancer care best practices.

2024 Fall Summit Resources

October 24, 2024

Thursday, October 24th Fall Summit Session Handouts A Review of Prostate Cancer & Recent Updates in the Treatment of Metastatic Prostate Cancer Addressing Cancer Disparities and SDOH Unique Rural Populations Advances in Breast Cancer Treatment and Current Updates Alphabet Soup Unlocking Acronyms in Pathology and Cancer Care Championing Patient Care: Highlighting the Varied Roles of […]
read more

MiBA and NCODA Partner to Launch Oncology Insights Program

October 22, 2024

Tampa, Fla. & Cazenovia, N.Y. October 22, 2024 – Meaningful Insights Biotech Analytics, LLC (MiBA) and the National Community Oncology Dispensing Association (NCODA) are pleased to announce their partnership on the launch of the Oncology Insights Program (OIP), an innovative and educational initiative powered by prescriber data. This collaboration aims to provide healthcare professionals (HCPs) […]
read more

NCODA APPOINTS FIVE NEW MEMBERS TO ITS EXECUTIVE COUNCIL

August 15, 2024

CAZENOVIA, NY, August 15, 2024  – NCODA is excited to announce the addition of five highly esteemed professionals to its Executive Council: Natalie Dickson, MD, Ken Komorny, PharmD, BCPS, Kim Le, PharmD, Wafa Samara, PharmD, and Nathan Shumway, DO, FACP. These new appointees bring a wealth of experience and dedication to the oncology field, reinforcing […]
read more

Carter, Barragán, Miller-Meeks successfully push Biden administration to protect patients’ access to life-saving medications

January 19, 2024

WASHINGTON, D.C. – Reps. Earl L. “Buddy” Carter (R-GA), Nanette Barragán (D-CA), and Mariannette Miller-Meeks (R-IA) today celebrated the Biden administration’s decision to drop its appeal in a case against the patient community, keeping in effect the District of Columbia’s District Court ruling affirming the 2020 Notice of Benefit and Payment Parameters (NBPP) Final Rule requiring that […]
read more

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

December 6, 2023

– Approval based on positive data from Phase 3 DeFi trial, in which OGSIVEO significantly improved progression-free survival and objective response rate, with rapid and sustained improvements in pain, physical functioning and overall quality of life – STAMFORD, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on […]
read more

World Leaders in Medically Integrated Oncology Set to Gather at NCODA’s 2023 Summit to Further Elevate Patient Care

October 23, 2023

– Integrated cancer care professionals to address treatments, shortages, and operational advances driving improved outcomes –   Orlando, FL – October 23, 2023 – Physicians, nurses, pharmacists, and other important clinical and administrative team members, along with partnering pharmaceutical industry representatives from all over the world will gather in Orlando October 25-27 for the NCODA […]
read more

Effective October 1, 2023, ICD-10-CM Diagnosis Codes Are Available for Desmoid Tumors

October 16, 2023

Desmoid tumors are rare, locally aggressive soft tissue tumors1 Until October 1, 2023, desmoid tumors fell under an ICD-10-CM code (D48.1) covering a variety of connective and soft tissue tumors of “uncertain behavior”2 As of October 1, 2023, ICD-10-CM diagnosis codes are available for desmoid tumors2   On October 1, 2023, location-specific International Classification of […]
read more

PAN announces opposition to alternative funding programs

June 14, 2023

JUNE 13, 2023 The PAN Foundation today announced opposition to alternative funding programs, which jeopardize patient access to specialty medications and redirect finite charitable funds away from uninsured and underinsured patients. We urge Congress and the administration to learn about the growing use of alternative funding programs, understand their detrimental impact on patients, and evaluate options […]
read more

FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis

May 25, 2023

May 22, 2023 at 4:04 PM EDT — For the first time, patients with indolent SM have a medicine that treats the primary disease driver and is proven to provide broad and durable symptom relief — — Approval based on the positive PIONEER trial, in which once-daily AYVAKIT achieved significant improvements in disease symptoms and […]
read more

CMS Guidance on Practices Delivering Medications Violating the Stark Law

April 27, 2023

[CAZENOVIA, NY – April 27, 2023] – NCODA urges the Centers for Medicare & Medicaid Services (CMS) to immediately retract a portion of a Frequently Asked Questions (FAQ) that suggests that physician practices mailing medications would violate the federal prohibition on self-referral for ancillary services (Stark law). At present, the Public Health Emergency (PHE) that […]
read more

RESOURCES

Cost Avoidance Waste Tracker

Positive Quality Interventions

PQI in Action

OCE Sheets

IVE Sheets

Treatment Support Kits

PQI Podcast

Members

Member Resources

OPTA

Committees

Member Login

Events

Webinars

Spring Forum

Oncology Institute

PSO Annual Meeting

Fall Summit

contact@ncoda.org

315-655-4640

P.O. Box 468
Cazenovia, NY 13035

NCODA Logo

NCODA is a 501(c)(3) Organization